Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma

Inclusion Criteria

* Age 18 to 70 years.
* Histologically proven non-Hodgkin's lymphoma
* High risk disease including at least one of the following:

  * Relapsed or refractory disease
  * Transformed lymphoma
  * Aggressive T-cell lymphoma
  * Failure to achieve completed remission (CR) following Auto SCT
  * Less than a 20% chance of event-free survival from autologous transplant determined by the treating physician and the Principal Investigator
* ECOG performance status \< or = 2
* Underwent Autologous SCT 60-120 days prior to registration including:

  * BEAM conditioning (BCNU: 300 mg/m2 IV day -7, Etoposide: 100 mg/m2 IV BID days -6,-5,-4,-3, Cytarabine: 100 mg/m2 IV BID days -6,-5,-4,-3, Melphalan: 140 mg/m2 IV day -2)
  * Minimum of 2 x 106 CD34+ cells/kg infused
* Full hematologic recovery following Auto HCT including:

  * Absolute neutrophil count (ANC) \>1000 µl
  * Platelet count of ≥50,000 µl independent of transfusion for \>7 days
* Available matched related or unrelated donor. Selected donor must be a complete match or have only a single antigen mismatch.
* Women of child-bearing potential and sexually active males must use an accepted and effective method of birth control.
* Bone marrow comprising of \< 10% lymphoma on most recent biopsy/aspiration (within 9 months of Allo transplant; may have been performed prior to autologous transplant).
* Serum bilirubin \< or = 2 x the institutional ULN
* Serum creatinine \< or = 2 x the institutional ULN and measured or estimated creatinine clearance \> 60 cc/min by the following formula

  * Estimated Creatinine Clearance = (140 age)X WT(kg) X 0.85 if female 72X serum creatinine(mg/dl).
* Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.

Exclusion Criteria

* Prior autologous or allogeneic hematopoietic cell transplantation (other than autologous SCT 60-120 days prior to registration)
* Prior radioimmunotherapy
* Known or suspected progressive disease following autologous SCT
* Additional treatment for NHL administered from time of autologous SCT through registration
* Pregnant or breast-feeding women (due to the known birth defects association with the treatments used in this study)
* Human immunodeficiency virus (HIV)-positive (the concern for opportunistic infection and hematologic reserve are considered to be significantly greater in this population.)
* Any prior malignancy is allowed except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer or other cancer for which the patients has been disease-free for five years.
* Active infection requiring oral or intravenous antibiotics.

Inclusion of Women and Minorities

-Both men and women and members of all races and ethnic groups are eligible for this trial.